• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Agispor Solution
    / Perrigo


    Active Ingredient
    Bifonazole 1gr / 100 ml

    Status in Israel
    OTC

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Solution

    15 ml

    full basket chart 7850 1813

    Dosage

    To achieve a lasting cure, treatment with AGISPOR cream, solution and gel must be carried out reliably and over an adequate period. The usual periods of treatment are:
    Foot mycoses (Tinea pedis, tinea pedum interdigitalis): 3 weeks.
    Mycoses of the trunk, hands and skin folds (Tinea corporis, tinea manuum,
    tinea inguinalis): 2-3 weeks.
    Pityriasis versicolor: 2 weeks.
    Erythrasma: 2 weeks.
    Superficial candidiasis of the skin: 2-4 weeks.
    Use in Children: No in-depth studies have been performed in children. From a survey of the clinical data reported there is no indication that harmful effects should be anticipated in children. However, in infants and toddlers, the medicinal product should only be used under medical supervision.
    Method of administration:
    Solution is used once a day, preferably in the evening, before retiring. It should be applied thinly to the affected skin area and rubbed in.
    A few drops (about 3 drops) is generally sufficient to treat an area of about the
    size of the palm of the hand.


    Indications

    Broad spectrum antimycotic agent.


    Contra-Indications

    Hypersensitivity to the active substance(s) or to any of the excipients.


    Special Precautions

    Pregnancy, lactation. Avoid contact with eyes.


    Side Effects

    Slight reddening, burning, irritation, scaling may occur rarely, usually transient.


    Drug interactions

    Limited data suggest that an interaction between topical bifonazole and warfarin may be possible, leading to increases in INR. If bifonazole is used in a patient on warfarin therapy, they should be appropriately monitored.


    Pregnancy and Lactation

    Pregnancy: Preclinical safety data and pharmacokinetic data in humans give no indication that harmful effects on the mother and child should be anticipated when bifonazole is used during pregnancy. However, no clinical data are available. As a precautionary measure, it is preferable to avoid the use of bifonazole during the first trimester of pregnancy.
    Lactation: It is unknown whether bifonazole is excreted in human breast milk.
    The excretion of bifonazole in milk has been studied in animals. Available pharmacodynamic/toxicological data in animals have shown excretion of bifonazole/metabolites in milk. Breast-feeding should be discontinued
    during treatment with bifonazole.


    Overdose

    No risk of acute intoxication is seen as it is unlikely to occur following a single dermal application of an overdose (application over a large area under conditions favorable to absorption) or inadvertent oral ingestion.


    Important notes

    Shelf-life: 60 months.
    Storage: store below 25°C.


    Manufacturer
    Perrigo Israel
    CLOSE